GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

New tests may show how much value a particular obese patient will get for a GLP-1 agonist prescription dollar.

I attended my high school reunion and had no anxiety about appearance,” Sarah gushed. “My new problem was graciously ...

The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...

As 2025 ushers in a new era of weight loss resolutions, many Americans are abandoning traditional gym-first approaches in ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Experimental weight-loss drug Retatrutide shows promise, helping obese adults lose up to 22% of their weight in 48 weeks.

How GLP-1 therapies could help build a healthier, more productive workforce—and what that would mean for how we live together ...

Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...

Surgeons are collaborating with obesity medicine physicians, turning to GLP-1s to help high BMI patients qualify for surgery.

Looking to expand its legacy in metabolic conditions, Novo Nordisk has inked a multiyear research pact with Variant Bio to better understand the genetics underlying disease across diverse populatio | ...

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic.